Recombinant IFN-γ and adenovirus vectors that express IFN-γ cDNA have been trialed clinically, with some success, for a range of diseases including chronic granulomatous disease, hepatitis, tuberculosis, and certain cancers (see Miller et al., 2009 for review). This evidence concerns the gene IFNG and tuberculosis.